TrialSpark | December 21, 2020
TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients.
Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug development partner, TrialSpark will support Anteris Bio utilizing its imaginative, tech-enabled clinical development model.
Aditum Bio, helped to establish by previous Novartis executives Joe Jimenez and Dr. Mark Fishman, is adopting another strategy to healthcare. Aditum Bio's central goal is to give huge patient populaces admittance to medicines which in any case may not be created. To improve access for patients and speed these drugs to market, Aditum Bio makes an individual "spin-out" organization to actualize Phase I and Phase II clinical preliminaries in partnership with TrialSpark. The "spin-out" has a lean, devoted group of supervisors that can drive quickened preliminary timetables and creative preliminary plans, utilizing TrialSpark's clinical trial platform and services.
CELL AND GENE THERAPY
CSL Plasma | March 11, 2022
CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval.
The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologies.
Additional characteristics of the new Rika system, according to CSL Plasma, will allow for the collection of more plasma in less time, hence improving quality and safety and, in turn, better serving patients who rely on plasma-based therapies. These advantages include:
On average, Rika completes one plasma collection in 35 minutes or less: Compared to previous average CSL Plasma donation timings, this might mean a nearly 30% reduction in donor donation time.
It assures that no more than 200 milliliters of blood are ever removed from the donor's body. This is believed to make the donor more comfortable during the donation process and lessen the risk of red cell loss deferral.
It has a sophisticated user interface that helps CSL Plasma front-line personnel operate the equipment.
This milestone helps bring to life how we demonstrate innovation, collaboration, and patient-focus, part of the CSL Values that underpin our commitment to manufacturing and delivering life-saving and life-extending medicines around the world, We continue to evolve as a leading biotechnology company, investing in our core plasma business. Continued innovation that benefits our employees and plasma donors speak to how we are driven by our promise to save and improve lives around the world."
CSL Chief Operating Officer Paul McKenzie.
CSL Plasma will begin installing the new technology at locations in the Denver, Colorado, area in the following months.
There is a critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases, CSL Plasma's decision to work with Terumo Blood and Cell Technologies is consistent with our business goals to improve the donor and employee experience through innovation and remain the plasma donation center of choice. We look forward to rolling out this new technology."
CSL Plasma General Manager Michelle Meyer.
Prellis Biologics, Inc. | January 14, 2022
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system based on human lymph node organoids. The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins.
Under the terms of the agreement, Prellis and Bristol Myers Squibb will collaborate on the generation of human antibody libraries for select targets. Prellis will receive from Bristol Myers Squibb an undisclosed up-front payment, funding for research activities, development, sales milestones and royalties for licensed antibodies.
"With industry leading speed, the EXIS platform provides high affinity antibodies, derived from lymph node organoids printed with Prellis’ foundational technology, using human PBMCs. We are looking forward to working with Bristol Myers Squibb to demonstrate advantages of in vitro human antibody discovery with the EXIS platform."
Melanie P. Matheu, PhD, Founder and CEO of Prellis Biologics
Kevin Chapman, PhD, CSO of Prellis, added, "The EXIS platform effectively breaks tolerance enabling direct discovery of human antibodies to challenging human antigens in less than two weeks."
Prellis Biologics, Inc. is the first company to develop a fully synthetic, animal-free, functional human immune system, EXIS™. The EXIS platform allows Prellis to harness fully human immune responses for the development of antibody therapeutics, disease models, and target discovery. With industry-leading speed and resolution, Prellis’ proprietary holographic printing technology is able to accurately match and rapidly replicate human organ and tissue structures. Prellis is dedicated to improving patient lives by discovering novel therapeutics, utilizing its unique capabilities in antibody discovery and in vitro human disease models. Prellis Biologics, Inc. was founded in 2016 and is a privately held company based in the San Francisco Bay Area.